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Pre-mRNA splicing takes place on a large ribonucleo-
protein particle, the spliceosome which contains the
five small nuclear ribonucleoproteins (snRNPs), U1, U2,
U4, U5, and U6. In Saccharomyces cerevisiae the mRNA
splicing factors, Prp9, Prp11, and Prp21, are necessary
for addition of the U2 snRNP to the pre-mRNA in an
early step of spliceosome assembly. This paper describes
a study of interactions between these proteins and their
role in spliceosome assembly. The proteins were ex-
pressed in Escherichia coli. Prp9 and Prp11 were puri-
fied by metal affinity chromatography. Prp21 was puri-
fied using a solubilization/renaturation protocol. We
have combined these separately purified proteins and
present direct evidence of a Prp9zPrp11zPrp21 protein
complex that is functional in in vitro splicing assays.
Characteristics of this Prp9zPrp11zPrp21 complex were
further investigated using proteins synthesized in
vitro. In addition, we found that Prp9, Prp11, and
Prp21 influence the structure of the U2 snRNP in a
manner that alters the accessibility of the branch
point pairing region of the U2 snRNA to oligonucleo-
tide- directed RNaseH cleavage. We present a model,
based on the data presented here and in the accompa-
nying paper, for a combined role of Prp9, Prp11, Prp21,
and Prp5 in activating the U2 snRNP for assembly into
the pre-spliceosome.
Eukaryotic pre-mRNA splicing is a dynamic process involv-
ing a complex array of RNA-RNA and RNA-protein interac-
tions (reviewed in Refs. 1 and 2). These interactions take place
on a large, multi-protein RNA complex called the spliceosome.
Assembly of the spliceosome occurs by ordered association of
five snRNPs1 with the pre-mRNA substrate. Initially, the U1
snRNP associates with the pre-mRNA, followed by the U2
snRNP and finally the U4/U6zU5 tri-snRNP. The two trans-
esterification reactions leading to intron removal and exon
ligation are thought to be catalyzed by the RNA components of
the spliceosome (reviewed in Ref. 3). The spliceosomal proteins
are thought to facilitate modulation and stabilization of RNA
structures critical for the splicing reaction.
A large number of proteins required for pre-mRNA splicing
have been identified in yeast (4, 5). Some of these proteins can
be found stably associated with specific snRNPs. Others are
components of spliceosome complexes. Yet another class of
splicing proteins acts transiently to facilitate spliceosome
formation.
The initial step in spliceosome assembly is the stable asso-
ciation of the U1 snRNP with the pre-mRNA (reviewed in Ref.
2). This step requires sequence elements in the pre-mRNA at
the 59 splice site and the branch point. Pre-spliceosome forma-
tion occurs when the U2 snRNP adds to the U1zpre-mRNA
complex. U2 binding also requires sequences in the branch
point pairing region of the pre-mRNA. These sequences become
paired to the complementary branch point region of the U2
snRNA (2). The branch point region of U2 is situated between
two highly conserved secondary structural elements (6). One of
these is the 59 stem-loop structure and the other is a set of
stem-loops with pseudoknot characteristics (7, 8). U2 cold-sen-
sitive mutations and revertants in this pseudoknot-like region
have suggested potential structural transitions that may be
important for U2 snRNP activities, including pre-spliceosome
formation (9, 10).
Four proteins known to be required for stable association of
the U2 snRNP with the pre-mRNA are Prp5, Prp9, Prp11, and
Prp21 (reviewed in Ref. 11). Prp5 is a member of the DEAD
family of putative RNA helicases (12), and Prp9 and Prp11
contain amino acid homology to the TFIIIA type zinc finger
RNA binding domains (13, 14). Prp21 is a member of a family
of proteins related in sequence to the Drosophila gene, suppres-
sor of white apricot (15). The finding that mutant alleles of the
PRP5, PRP9, PRP11, and PRP21 genes show synthetic lethal
genetic interactions suggested a tightly coupled role for the
corresponding proteins in splicing (16, 17). That these proteins
also interact genetically with the cold-sensitive U2 mutations
described above suggested that changes in the structure of the
U2 snRNAmay be critical to the activities of Prp5, Prp9, Prp11,
and Prp21 (16, 17). Pre-spliceosome formation requires ATP
hydrolysis. Because Prp5 is an RNA-dependent ATPase (18), it
is tempting to speculate that Prp5 is responsible, at least in
part, for the ATP dependence of pre-spliceosome formation.
Could such an ATP-dependent reaction by Prp5 be coupled to
U2 snRNA structural changes and the activity of Prp9, Prp11,
and Prp21? To better understand these genetic interactions, we
have purified the Prp9, Prp11, and Prp21 proteins using re-
combinant Escherichia coli expression systems. Purification of
these proteins has allowed us to investigate their biochemical
characteristics and their interactions with Prp5 and the U2
snRNP.
MATERIALS AND METHODS
Plasmid Construction—The following oligonucleotides were used in
the cloning manipulations described below: 1) 59CATCATCTCCATG-
GATTTACTTG; 2) 59CAGAGGATCCTCACACCAAACC; 3) 59CCTC-
GACCATGGACTTGTCGTCGTCGTCGAT; 4) T7 promoter sequencing
primer; 5) 59CATAGAATTCATATGAACTATTTAGAAG; 6) 59CAAGA-
ATTCGGATCCTACTGTCATACATC.
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Several Prp9, Prp11, and Prp21 E. coli expression vectors were
constructed and used in these experiments. To construct the plasmid
pET-Prp9, the Prp9 coding region of the plasmid pPrp9–39HA (kindly
provided by M. Rosbash, Brandeis University) was amplified by the
polymerase chain reaction (PCR) with oligonucleotides 1 and 2 de-
scribed above. This generated NcoI and BamHI restriction site at the 59
and 39 ends, respectively. The resulting fragment was digested with
NcoI and BamHI and ligated into pET16b (Novagen, Inc., Madison, WI)
restricted with the same enzymes. The normal amino acid at position 2
of Prp9 is Asn. However, due to the conversion of the sequence at this
position to an NcoI site the amino acid at the second position was
changed to Asp. The dideoxy chain termination DNA sequencing
method was used to verify the sequence of the Prp9 insert. To construct
the His-tagged Prp9 expression vector the His-tag region from pET19b
(Novagen) was PCR-amplified with primers 3 and 4 described above.
The downstream primer generated an NcoI site just after the His-tag
region. The resulting PCR fragment was digested with NcoI, and the
His-tag fragment was ligated into pET-Prp9 (described above). Protein
expressed from this plasmid has the following amino-terminal se-
quence: M(H)10SSGHIDDDDKS–MD. The penultimate Met immedi-
ately following the dash corresponds to the original Met of Prp9. The
Asp at the normal second position is changed from an Asn as described
above.
To construct the plasmid pET-HisPrp11, the coding region of Prp11
was amplified from the plasmid pPrp11-cen (16). Sequences for NdeI
and BamHI were included in the amplifying primers. The resulting
PCR fragment was digested with NdeI and BamHI and ligated into
pET19b restricted with the same enzymes. Protein expressed from this
plasmid contains the following amino-terminal sequence: M(H)10SS-
GHIDDDDKS–MN. The two amino acids following the dash represent
the first two amino acids of the Prp11 coding region. The DNA sequence
of the Prp11 insert was verified by sequencing as described above. To
construct the plasmid pET-Prp11, pET-HisPrp11 was digested with
NdeI and BamHI, and the resulting Prp11 fragment was isolated. This
fragment was ligated into pET11a (Novagen) restricted with NdeI and
BamHI. The Prp21 expression plasmid pET-Prp21, was described pre-
viously (19). To construct pET-HisPrp21 the NdeI fragment from pET-
Prp21 containing Prp21 DNA sequences was ligated into the NdeI site
of pET-19b. DNA sequencing as described above was used to verify the
correct orientation of the insert.
Protein Purification—Expression and purification of His-Prp9 was
performed in the E. coli strain HMS-pLysS. Expression levels for His-
Prp9 in this strain were slightly better than in BL21, albeit still ex-
tremely low. To purify Prp9, competent E. coli cultures were freshly
transformed. Cells were used within 24 h of transformation to inoculate
an overnight culture. The following day, 3 liters of broth was inoculated
with 5 ml of the saturated overnight culture. The culture was grown to
an A600 of 0.6, at which time isopropyl-D-thiogalactopyranoside was
added to a final concentration of 0.8 mM. After 31⁄2 h of growth at 37 °C,
cells were harvested by centrifugation at 5000 3 g. From this point all
manipulations were performed at 4 °C. Pelleted cells were resuspended
in 95 ml of buffer IMAC5 (20 mM Tris-HCl, pH 7.5, at room tempera-
ture, 0.5 M NaCl, 10% glycerol, 5 mM imidazole) 1 1 mM phenylmeth-
ylsulfonyl fluoride. Cells were lysed on ice by four repeated rounds of a
30-s sonication followed by a 30-s rest. The lysate was cleared by
centrifugation and the supernatant was recovered. The lysate was
diluted to #10 mg/ml protein and loaded onto a 2-ml Ni-NTA (Quiagen)
column equilibrated in IMAC5. The column was washed with 40 ml of
IMAC5 followed by 20 ml of IMAC25 (same as above except 25 mM
imidazole). His-Prp9 was stepped off the column with IMAC200 (same
as above except 200 mM imidazole). Protein-containing fractions were
pooled and dialyzed against P9 buffer (20 mM Tris-HCl, pH 7.9, at 4 °C,
100 mM KCl, 0.2 mM EDTA, 20% glycerol). Protein was stored frozen at
270 °C at a concentration of 2 mg/ml. His-Prp9 purified in this manner
was 40–50% pure as determined by SDS-PAGE and staining with
Coomassie Blue. The majority of contaminating protein was repre-
sented by a single band at 25–30 kDa.
Expression and purification of His-Prp11 was performed in the E.
coli strain BL21. Transformation, growth, and isopropyl-D-thiogalacto-
pyranoside induction of cells were as described above for His-Prp9, as
was cell harvest and lysate preparation except that His-Prp11 contain-
ing cells were lysed in buffer containing 100 mM KCl, 20 mM Tris-HCl,
pH 7.9, at 4 °C, 0.2 mM EDTA, 20% glycerol, and 1 mM phenylmethyl-
sulfonyl fluoride. His-Prp11 was purified by chromatography on S-
Sepharose prior to Ni-affinity chromatography. The cell lysate was
loaded onto a 5 ml of S-Sepharose column. The column was washed with
the same buffer described above except lacking EDTA. His-Prp11 was
stepped off the column in buffer containing 500 mM KCl, 20 mM Tris-
HCl, pH 7.9, at 4 °C, and 20% glycerol. Fractions containing protein
were pooled, and KCl and imidazole were added to final concentrations
of 0.5 M and 5 mM, respectively. The protein was loaded onto a 2 ml
Ni-NTA column and chromatographed as described above for His-Prp9.
Eluted His-Prp11 was dialyzed against P11 buffer (20 mM Tris-HCl, pH
7.9, at 4 °C, 20% glycerol, 0.2 mM EDTA, 1 mM ZnCl2, and 0.5 M KCl).
Protein was stored at 270 °C at a concentration of 0.2 mg/ml. His-Prp11
purified in this manner was .90% pure as determined by SDS-PAGE
and silver staining.
Prp21 was purified in BL21 from inclusion bodies. Transformation,
isopropyl-D-thiogalactopyranoside induction, and cell lysis were as de-
scribed above. After centrifugation of the lysate, the inclusion body
pellet was recovered and transferred to a chilled glass beaker. Solubi-
lization buffer (10 mM HEPES, pH 7.9, 6 M guanidine HCl, 0.2 mM
EDTA, 0.2 mM EGTA, and 10 mM dithiothreitol) was added, and the
mixture was stirred gently for 8 h at 4 °C. Cellular debris was removed
by centrifugation at 18,000 rpm in an SS34 rotor. The supernatant was
diluted to 1 M guanidine with solubilization buffer lacking guanidine.
The sample was then dialyzed against 20 mM HEPES, pH 7.9, 20%
glycerol, 0.1 M KCl, 0.2 mM EDTA, 0.2 mM EGTA, and 2 mM dithiothre-
itol. Prp21 protein was stored at 270 °C at a final concentration of 0.2
mg/ml. Prp21 protein purified in this manner was $90% pure as deter-
mined by silver staining of SDS-PAGE. For some experiments described
below, Prp21 protein purified in the above manner was added to puri-
fied His-Prp11, and the combination was repurified on Ni-NTA. This
chromatography step resulted in recovery of equimolar amounts of
His-Prp11 and Prp21 when excess Prp21 was present in the mixture.
In Vitro Translation and His-tagged Protein Binding Assays—
mRNAs for tagged and untagged Prp9, Prp11, and Prp21 were synthe-
sized in vitro with T7 RNA polymerase from the above expression
vectors restricted with HindIII. mRNA was purified by phenol/CHCl3
extraction and ethanol precipitation. In vitro translation reactions were
performed with a rabbit reticulocyte kit (Promega). Reactions were
performed as per manufacturer’s instructions. Briefly, a mixture con-
sisting of reticulocyte, RNase inhibitor, amino acids minus methionine,
and [35S]methionine (DuPont NEN) was added to a specific mRNA that
had been preheated at 65 °C in H2O. The amount of mRNA for each Prp
synthesis required for maximum yield of translation product was em-
pirically determined in test reactions. This amount varied for different
Prp mRNAs. Reactions were incubated for 60 min at 30 °C. Samples
subjected to SDS-PAGE analysis were precipitated with four volumes of
acetone at 20 °C for $30 min. Recovered pellets were resuspended in
SDS buffer and loaded on an SDS-PAGE gel. 35S-Labeled products were
visualized by autoradiography.
Protein-protein binding assays were performed with in vitro trans-
lation products consisting of one His-tagged protein and one or more
non-tagged proteins. For most assays, 35S-labeled proteins were com-
bined immediately after synthesis at 30 °C. The mixture was incubated
for 20 min at 30 °C and then added to 300 ml of IMAC5 containing
10–15 ml of Ni-NTA beads (Quiagen resin). This mixture was incubated
on a rotator at 4 °C for 1 h. Beads were pelleted and the supernatant
was recovered. Beads were then washed three consecutive times with 1
ml of IMAC5. Beads were then resuspended in 300 ml of IMAC25 and
incubated 20 min. Beads were pelleted; the supernatant was recovered,
and beads were again washed in IMAC25 as described above. The
procedure was repeated with IMAC50. Finally, beads were resuspended
in 300 ml of IMAC200, incubated for 20 min, and the supernatant from
this final incubation was recovered. Each supernatant described above
was precipitated with four volumes of acetone and the pellets were
subjected to SDS-PAGE as described above.
Yeast Extract Preparation and in Vitro Splicing Assays—Yeast ex-
tracts from the temperature-sensitive strains prp9-1, prp11-1, and
prp21-1 were prepared as described previously (20). Mutant extracts
were inactivated by incubation at 37 °C for 25–30 min, except for the
prp21-1 extract which was heat-inactivated by incubation at 39 °C for
7–8 min. Splicing assays using a synthetic yeast actin pre-mRNA
substrate were as described previously (20). Splicing assays with heat-
inactivated mutant extracts reconstituted with purified protein were
generally performed by addition of protein to the heat-treated extracts,
followed by addition of splicing buffer and actin pre-mRNA substrate to
initiate the reaction. In the experiment of Fig. 2, some reactions were
performed by addition of purified protein to the mutant extract prior to
heat treatment, as indicated in the legend. The amount of purified
protein required to reconstitute splicing activity in heat-treated prp9-1,
prp11-1, and prp21-1 extracts was typically 1–10 nM. It is difficult to
estimate endogenous levels of these proteins in normal yeast extracts
because our antibodies do not detect Prp9, Prp11, or Prp21 in Western
blots of crude extracts. However, if the concentration of these proteins
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is comparable to the concentrations of snRNPs in active extracts (5 nM)
then the recombinant proteins are quite active.
RNaseH Structure Probing—RNaseH digestion of U2 snRNA in mu-
tant extracts and analysis of cleaved U2 snRNA were performed as
described in the accompanying paper (18).
snRNA Reconstitution and Immunoprecipitation—The protocols for
knock out and reconstitution of endogenous U6 and U2 snRNA in wild
type yeast extracts described by Fabrizio et al. (21) and McPheeters et
al. (22) were used to reconstitute extracts with synthetic radiolabeled
U2 and U6 snRNAs. Briefly, wild type yeast extract was incubated with
either the d1 oligo (140 nM final concentration) for U6 knockout or the
SRU2 oligo (200 nM final concentration) for U2 knockout under splicing
reaction conditions (60 mM phosphate, 3 mM MgCl2, 6 mM ATP, 3%
polyethylene glycol, 1.2 mM spermidine, and 10 mM dithiothreitol) for 30
min at 30 °C. Synthetic U2 snRNA or U6 snRNA, labeled by transcrip-
tion in reaction mixtures containing [a-32P]UTP, was then added fol-
lowed by H2O or actin pre-mRNA splicing substrate. Reactions were
incubated for 15–20 min at room temperature and then added to an
equal volume of antibody attached to protein A-Sepharose beads (PAS).
Antibody attached to PAS was prepared as described by Arenas and
Abelson (19). Mixtures were incubated for 30 min on ice with frequent
mixing of the components. Beads were pelleted and washed three times
in NET2 buffer (40 mM Tris-HCl, pH 7.5, at room temperature, 150 mM
NaCl, 0.05% Triton). Beads were then proteinase K-treated and pro-
cessed as described previously for splicing reactions (20). Recovered
RNA was analyzed by denaturing gel electrophoresis. Immunodepletion
of spliceosomal complexes by Prp21 antibodies was performed as de-
scribed by Arenas and Abelson (19). For immunodepletion of reactions
performed in prp2-1 mutant extracts, the extract was heat-inactivated
for 30 min at 37 °C prior to reaction with actin pre-mRNA substrate.
RESULTS
Purification of Prp9, Prp11, and Prp21 Proteins—To begin to
investigate the mechanism of action of Prp9, Prp11, and Prp21
in pre-mRNA splicing, we have purified the three proteins
using bacterial expression systems. Purification of Prp9 and
Prp11 was facilitated through the use of amino-terminal, nickel
affinity tags and IMAC as described under “Materials and
Methods.” Expression of Prp21 in E. coli leads to production of
highly insoluble material (19); therefore, a strategy for solubi-
lization and renaturation of Prp21 from inclusion bodies was
designed and is described under “Materials and Methods.”
Each of our purified proteins was tested in in vitro splicing
assays for the ability to restore splicing activity to the corre-
sponding mutant yeast extract. As shown in Fig. 1 heat inac-
tivation and reconstitution of extracts from the prp9-1 mutant
strain with purified Prp9 protein were efficient (lanes 4–6)
with reconstitution giving splicing levels similar to that of wild
type extracts. Reconstitution of splicing activity of extracts
from the prp11-1 or prp21-1 mutant strains was consistently
less efficient. It was previously noted by Chang et al. (14) that
reconstitution of prp11-1 extracts with in vitro translated
Prp11 protein required addition of the protein to the extract
prior to heat treatment. We therefore tested this protocol with
our purified Prp11 and Prp21 proteins. In the experiment of
Fig. 2, Prp11 protein was added either before or after heat
treatment of a prp11-1 mutant extract. Addition of Prp11 pro-
tein restored splicing to a significant level only when added
before heat treatment (compare lanes 3 and 4). The observation
that heat treatment of the prp11-1 mutant extract resulted in
permanent inactivation of the extract led Chang et al. (14) to
propose that Prp11 may be an integral part of a complex whose
components were also inactivated upon heat treatment of the
mutant extract. To test the possibility that a Prp9, Prp11,
Prp21 complex was inactivated in these heat treatments, we
assayed for reconstitution of splicing when combinations of
Prp9, Prp11, and Prp21 protein were added either before or
after heat inactivation of the prp11-1 mutant extract. The
ability to reconstitute splicing by proteins added after heat
treatment could only be detected when all three proteins were
added (lane 8). This finding indicates that heat treatment of
extracts containing the prp11-1 allele also leads to inactivation
of Prp9 and Prp21. Experiments performed with the three
purified proteins and the prp21-1 mutant extract showed sim-
ilar results, indicating that heat treatment of extracts contain-
ing the prp21-1 allele leads to inactivation of Prp9 and Prp11 in
addition to Prp21 (lanes 11–18).
Prp9zPrp11zPrp21 Complex Formation in Vitro—In an at-
tempt to characterize the putative Prp9zPrpz11zPrp21 complex,
we investigated other methods to obtain the three proteins in
active form. We synthesized these proteins in vitro utilizing a
rabbit reticulocyte lysate for translation of synthetic mRNAs
corresponding to each of the three proteins. The polypeptides
were synthesized with [35S]methionine, and, as shown in Fig.
3A, each translation product has the predicted molecular
weight. Each of these in vitro translated proteins reconstitutes
splicing activity in the corresponding heat-treated mutant ex-
tract (data not shown).
Several previous experiments suggested that Prp9, Prp11,
and Prp21 formed a complex in vivo (16, 23, 24). To test for
complex formation in the absence of other yeast proteins or
snRNA’s, we utilized our nickel affinity-tagged constructs to
test for protein-protein interaction based on co-purification of
untagged with tagged protein. The protocol for the binding
experiment is diagrammed in Fig. 3B. In vitro translated pro-
teins were prepared in separate translation reactions. The
reactions were combined, incubated briefly, and added to Ni-
NTA resin in buffer containing 5 mM imidazole. The mixture
was then spun to pellet the beads and the supernatant re-
moved. Beads were washed repeatedly in this fashion in 5 mM
Imidazole buffer. Buffer containing increasing concentrations
of Imidazole was then used to successively wash the beads, and
the supernatants were analyzed by SDS-PAGE. Results of an
experiment with His-tagged Prp11 and untagged Prp9 and
Prp21 are shown in Fig. 3C. In the experiment of lanes 1–5,
reactions were combined such that the His-Prp11 protein was
present at a reduced molar ratio relative to the untagged pro-
teins. When a mixture of tagged Prp11 and untagged Prp9 and
Prp21 were added to the beads, both Prp21 and Prp9 co-bound
with tagged Prp11, as illustrated by their presence in the 55
FIG. 1. Reconstitution of splicing activity in prp9-1 mutant
extracts with purified Prp9 protein. Splicing assays with an actin
pre-mRNA substrate were performed as described under “Materials
and Methods” with 4 liters of extract from the prp9-1 strain in a total
reaction volume of 10 ml. Reactions were for 50 min at 15 °C. In the
reactions of lane 1, the prp9-1 extract did not receive heat treatment,
whereas in lanes 2–6 the extract was heated at 37 °C for 30 min
(indicated by D). For the reactions in lanes 3–6, increasing concentra-
tions of His-Prp9 protein were added and constituted 1⁄10 of the total
reaction volume. In reactions where His-Prp9 protein was not added,
H2O (lanes 1 and 2) or buffer (lane 3) was added instead.
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and 200 mM Imidazole washes (lanes 3 and 4). Control experi-
ments in which the His-tagged protein was omitted from the
binding reaction and only Prp9 and Prp21 were incubated with
the beads resulted in elution of both proteins in the 5 mM
Imidazole supernatant (lane 11). The elution profile of His-
Prp11 alone is similar to that observed when Prp9 and Prp21
are present (lanes 6-10). The specific activity of each of the in
vitro translated proteins was determined, and the amount of
each protein in the 55 and 200 mM Imidazole elutions was
measured as described under “Materials and Methods.” In the
elutions of lanes 3 and 4, equimolar amounts of Prp11 and
Prp21 were obtained. A 3–4-fold lower amount of Prp9 was
observed in these lanes. The experiment of Fig. 3C was re-
peated multiple times, varying the relative molar ratios of the
tagged to untagged proteins. In all experiments where the
input amount of Prp21 relative to His-tagged Prp11 was one or
greater, the recovered molar ratio of Prp11 to Prp21 was 1. We
had difficulty producing large quantities of Prp9 in vitro and
were therefore unable to load a large excess of Prp9 relative to
Prp11; thus the relative molar ratio of Prp9 to Prp11 in these
experiments was consistently at or below 1.
The His-tag/Ni-binding experiments described above were
also performed with combinations of Prp9zPrp11zPrp21 in
which either Prp9 or Prp21 contained the His-tag. The in vitro
synthesized Prp21 and Prp9 with amino-terminal His-tags
were first tested to ensure their activity in reconstitution of
splicing in mutant yeast extracts (data not shown). Table I
summarizes the results of the binding assays. Also included is
a summary of the results from the binding studies in Fig. 3C. In
pairwise experiments we consistently observed co-elution of
Prp11 and Prp21, Prp9 and Prp21, and Prp21 with both Prp11
and Prp9. In experiments which tested for co-elution of two
untagged proteins with one tagged protein, we consistently
observed co-elution of the two untagged proteins, regardless of
which protein was tagged. Taken together, these results are
most consistent with a model for the Prp9zPrp11zPrp21 complex
in which the interactions are contributed for the most part in
highly stable pairwise interactions of Prp9 with Prp21 and
Prp11 with Prp21. In addition, quantitation of the molar ratios
of proteins in the pairwise combinations and in the three pro-
tein experiments described above strongly support there being
equimolar amounts of Prp9, Prp11, and Prp21 in the complex
(data not shown).
Functional Interaction between Prp5 and Prp9zPrp11zPrp21—
There are several lines of evidence suggesting that Prp5 may
interact with Prp9, Prp11, and Prp21. First, the four proteins
are required at the same step in spliceosome assembly, namely
the stable addition of U2 snRNP to the pre-mRNA (2, 11).
Second, combinations of pairs of the temperature-sensitive al-
leles of Prp5, Prp9, Prp11, and Prp21 show a synthetic lethal
phenotype in vivo (16, 17). The most likely mechanism for the
observed synthetic lethality between Prp9, Prp11, and Prp21 is
the inactivation of the Prp9zPrp11zPrp21 complex. It is possible
that a similar interaction explains the genetic interaction be-
tween Prp5 and Prp9, Prp11, or Prp21. We therefore tested for
a direct interaction between Prp5 and the Prp9zPrp11zPrp21
complex using the His-tag/nickel binding experiment described
above. Under all conditions tested we were unable to detect
significant binding of Prp5 to Prp9zPrp11zPrp21 (data not
shown). Prp5 synthesized in vitro was active in reconstitution
of splicing activity in prp5-1 mutant yeast extracts (data not
shown). This was also the case for binding assays performed in
the presence of a molar excess of synthetic U2 snRNA or
pre-mRNA (data not shown). Our inability to detect a stable
interaction between Prp5 and Prp9zPrp11zPrp21 suggests that
the genetic interactions between Prp5, Prp9, Prp11, and Prp21
may be mediated through a functional rather than a physical
interaction between these proteins, i.e. the four proteins may
be acting on the same substrate.
Several lines of evidence suggest that Prp9, Prp11, Prp21,
and Prp5 act in conjunction with the U2 snRNP (16, 17). In the
accompanying paper (18) we employ an RNaseH structure
probing assay to show that Prp5 plays a role in an ATP-
mediated structural change of the U2 snRNP. In the experi-
FIG. 2.Reconstitution of splicing activity in prp11-1 and prp21-1mutant extracts with purified Prp9zPrp11zPrp21 complex. Splicing
assays as described in the legend of Fig. 1 were performed with extracts from the prp11-1 mutant strain (lanes 1–10) and with extracts from the
prp21-1mutant strain (lanes 11–18). In the reactions of lanes 2–18, mutant extracts were heated in the absence (even numbered lanes) or presence
(odd numbered lanes) of added purified protein. For the reactions heat-treated in the absence of added purified protein, the indicated proteins were
added after heat treatment (except lanes 2 and 12) and before initiation of the splicing reaction by addition of splicing buffer and actin pre-mRNA.
The combination of proteins added to each reaction is indicated above the lane. Heat treatment of mutant extracts was for 25 min at 37 °C (prp11-1
mutant extracts, lanes 2–10) or for 8 min at 39 °C (prp21-1 mutant extracts, lanes 12–18). In reactions containing the two proteins His-Prp11 and
Prp21 (lanes 5–8 and 15–18), the source of protein was His-Prp11 and Prp21 co-purified on Ni-NTA as described under “Materials and Methods.”
In reactions to which all three Prps were added (lanes 7, 8, 17, and 18), the purified proteins were mixed at the appropriate dilution prior to addition
to the heat-treated extract.
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ments shown in Fig. 4A we tested the importance of Prp9,
Prp11, and Prp21 in this Prp5-mediated conformational change
in the U2 snRNP. The extent of cleavage of the U2 snRNP upon
addition of a deoxy oligonucleotide complementary to the
branch point pairing region of the U2 snRNA was measured in
wild type and prp9-1 extracts. Incubation of heat-treated wild
type extracts with the branch point oligonucleotide shows nor-
mal levels of U2 cleavage (Fig. 4A, lane 2). The level of cleavage
in the wild type extract is enhanced upon addition of ATP (lane
3). In heat-inactivated prp9-1 extracts cleavage of U2 occurs
independently of the presence of ATP (lanes 5 and 6). As shown
in lanes 7 and 8, when purified Prp9 protein is added to the
heat-treated prp9-1 extract, oligonucleotide-directed cleavage
again shows an enhancement upon addition of ATP. We also
performed RNaseH structure probing experiments with ex-
tracts from prp11-1 and prp21-1 mutant strains. As with the
prp9-1 mutant strain, heat-inactivated prp11-1 and prp21-1
extracts exhibit a high level of branch point oligonucleotide-
directed cleavage of U2 RNA in the presence or absence of ATP.
However, when cleavage is monitored in prp11-1 and prp21-1
mutant extracts to which the appropriate purified protein has
been added, we still observe a high level of cleavage even in the
absence of added ATP (data not shown). We believe the latter
observation is related to the fact that heat inactivation of
mutant extracts of these two alleles can cause irreversible
inactivation of splicing activity. Even though in the experi-
ments described above we added the purified proteins prior to
heat treatment, restoration of activity is still minimal (see Fig.
2). These structure probing experiments indicate that inacti-
vation of Prp9zPrp11zPrp21 favors formation of a U2 snRNP
conformation that is not sensitive to the action of Prp5 and
ATP. Although the branch point region in this U2 snRNP
FIG. 3. Prp9zPrp11zPrp21 complex
formation in vitro. A, 35S-labeled pro-
teins were synthesized by in vitro trans-
lation as described under “Materials and
Methods.” An aliquot of the reaction was
acetone-precipitated, processed, and ana-
lyzed by SDS-PAGE. An autoradiogram
from the gel is shown. The specific mRNA
used in the translation reaction is indi-
cated above each lane. B shows a diagram
of the protein binding experimental pro-
tocol. Binding reactions were performed
as detailed under “Materials and Meth-
ods.” C, equal amounts of supernatants
recovered by successive elutions from
beads with increasing concentrations of
Imidazole were processed and analyzed
on an 8% SDS-PAGE. An autoradiogram
of the gel is shown. The concentration of
Imidazole corresponding to the elution
sample is indicated above each lane.
Lanes labeled Load represent an aliquot
of the protein mixture prior to addition to
the Ni-NTA beads. Lanes 1–5 show bind-
ing reactions performed with combined
translation products from reactions with
His-Prp11, Prp9, and Prp21 mRNAs.
Lanes 6–10 and 11–15 show elutions from
binding reactions performed with prod-
ucts from translation reactions with His-
Prp11 mRNA only and with Prp9 and
Prp21 mRNAs, respectively.
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conformation is open and accessible to cleavage, the snRNP is
not functional because of the absence of Prp9, Prp11, and
Prp21. In the presence of Prp9, Prp11, and Prp21, the U2
snRNP conformation becomes inaccessible to cleavage and can
only be “opened” by the action of Prp5 and ATP.
To further investigate the importance of the U2 snRNP
structural changes described above, we applied the RNaseH
structure probing technique to extracts of the two cold-sensi-
tive U2 snRNA mutants G53A and C62U (9, 10). Both of these
point mutations exhibit a synthetic lethal phenotype with the
temperature-sensitive mutants prp5-1, prp9-1, prp11-1, and
prp21-1 described above (16, 17). Extracts from these two mu-
tant U2 strains are active at a low level in in vitro splicing
reactions performed at 30 °C but not at 15 °C. When extracts
from the G53A and C62U strains were tested with the branch
point oligonucleotide for RNaseH degradation at 30 °C, we
observed the same level of cleavage in the presence or absence
of ATP (see Fig. 4B). We attempted to perform the RNaseH
degradation experiments at the nonpermissive temperature of
15 °C; however, RNaseH activity could not be observed at this
temperature even in wild type extracts (data not shown). Thus,
the U2 snRNP conformation in these U2 mutants is similar to
that of U2 snRNP formed in the absence of Prp9, Prp11, and
Prp21 in that branch point region is accessible to cleavage in
the absence of ATP.
Prp21 and Prp11 Are in a U6-containing Spliceosomal Com-
plex—Prp9, Prp11, and Prp21 are known to be required for
formation of the pre-spliceosome, a complex containing only the
U1 and U2 snRNAs (2, 11). In addition, each of the three
proteins has been shown to be a component of the pre-spliceo-
some. The mammalian counterparts to Prp9, Prp11, and Prp21
(SAP61, SAP62, and SAP114) have been found associated with
spliceosomal complexes more mature than the pre-spliceosome
(25, 26). In early experiments designed to identify spliceosomal
complexes containing Prp21, we used an antibody depletion
experiment to show that Prp21 was an integral component of
the pre-spliceosome (19). However Prp21 did not appear to be
present at later stages of assembly because complexes A2-1,
A1, and A2-2 were not depleted. We therefore devised a highly
sensitive co-immunoprecipitation assay to test for the presence
of Prp21 and Prp11 in more mature spliceosomal complexes
that contain U6. Our assay makes use of the knockout/recon-
stitution protocol for the U6 snRNA developed by Fabrizio et al.
(21). Using wild type extracts, we depleted endogenous U6
snRNA by incubation with the d1 oligonucleotide. We then
reconstituted the extract with a radiolabeled, in vitro synthe-
sized, U6 transcript and performed immunoprecipitations with
antibodies to either Prp21 or Prp11. Precipitated fractions were
analyzed on a denaturing gel to determine the extent of U6
RNA co-precipitation. As shown in Fig. 5, synthetic U6 snRNA
co-immunoprecipitates with antibodies to Prp21 and Prp11, in
the presence but not the absence of added actin pre-mRNA
(compare lanes 3-6 and 9-12). This pre-mRNA-mediated U6
co-immunoprecipitation is dependent on a functional 59 splice
site in the actin pre-mRNA (data not shown). In addition, U6 is
not co-immunoprecipitated in the absence of ATP, even when
wild type pre-mRNA is added (data not shown).
Immunoprecipitations performed with the pre-immune se-
rum for Prp21 showed levels of U6 binding at or below the level
seen with the Prp21 antibodies in the absence of added
pre-mRNA (data not shown). In other lanes of the experiment
of Fig. 5, we depleted wild type extracts of endogenous U2
snRNA by oligonucleotide-directed RNaseH cleavage and re-
FIG. 4.RNaseH structure probing of the U2 snRNP in Prp9 and
U2 mutant extracts. A, wild type (lanes 1–3) or heat-inactivated
prp9-1mutant extracts (lanes 4–7) were incubated with SRU2 oligo (bp
oligo), lanes 2, 3 and 5–8) or H2O (lanes 1 and 4) in the presence or
absence of 3 mM ATP as indicated above each lane. In the reactions of
lanes 7 and 8, purified His-Prp9 protein was added to the extract after
heat treatment and prior to oligo addition. After oligo treatment at
30 °C for 30 min, reactions were processed, and the U2 snRNA was
analyzed by Northern blot hybridization as described under “Materials
and Methods.” Uncleaved (i.e. full length) U2 snRNA is indicated by the
uppermost arrow labeled U2. RNaseH cleaved U2 is indicated by the
two arrows labeled Digested U2. Probes for U1 snRNA were also in-
cluded in the hybridization as a standard for the amount of RNA sample
loaded. B, similar experiments as described above in A, except extracts
were wild type (lanes 1–3), mutant U2G53A (lanes 4–6), and mutant
U2C62U (lanes 7–9). bp, base pair.
TABLE I
Prp9, Prp11, and Prp21 protein-protein interactions in vitro
His-tagged
protein Test proteins
Co-elution
from Ni-Beads
Prp11 Prp9 No
Prp21 Yes
Prp11a No
Prp9 and Prp21 Yesb
Prp9 Prp11 NDc
Prp21 Yes
Prp9a No
Prp11 and Prp21 Yesb
Prp21 Prp9 NDc
Prp11 Yes
Prp9 and Prp11 Yesb
a Tagged and untagged proteins were synthesized in the same trans-
lation reaction prior to the binding test.
b Indicates both test proteins co-elute.
c ND, not determined.
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constituted with a synthetic radiolabeled U2 RNA (22). In this
set of experiments we compared the ability of Prp21 and Prp11
antibodies to co-immunoprecipitate a full-length U2 RNA or
the internal deletion known as D107 (described under “Mate-
rials and Methods”). As expected, we observed co-immunopre-
cipitation of full-length U2 in the presence and absence of
added actin pre-mRNA (lanes 1, 4, 7, and 10). This is consistent
with earlier antibody precipitation experiments that showed
that Prp21 associates with the endogenous U2 snRNP and the
pre-spliceosome (19). We observed similar levels of co-immuno-
precipitation of radiolabeled U2 snRNA in the presence or
absence of pre-mRNA, whereas previous studies found that
co-precipitation of endogenous U2 is enhanced by added
pre-mRNA (19). The lack of an enhancement of U2 binding by
added pre-mRNA in the reconstitution protocol may be due to
the use of very low levels of active U2 snRNA. Precipitation of
the U2D107 RNA showed a similar pattern of binding com-
pared with the full-length U2 but occurred at an overall re-
duced efficiency (lanes 2, 5, 8, and 11).
The finding that antibodies to Prp21 and Prp11 immunopre-
cipitate U6 in a pre-mRNA-dependent manner indicate that
Prp21 and Prp11 bind to a spliceosomal complex which is more
mature than the pre-spliceosome. Although we did not have
antibody to Prp9, our finding that Prp9, Prp11, and Prp21 form
a highly stable complex under similar in vitro conditions sug-
gests that Prp9, as part of the 9.11.21 complex, is also associ-
ated with a U6-containing spliceosomal complex.
Prp21 Is a Component of the A1 Complex—To identify spe-
cific spliceosomal complexes containing the Prp11 and Prp21
proteins, we performed immunodepletion experiments similar
to those of Arenas and Abelson (19). The protocol involves
incubation of splicing reactions with antibody beads followed
by a brief centrifugation to pellet complexes to which the anti-
body has bound. A fraction of the supernatant is then loaded to
a native polyacrylamide gel, and spliceosomal complexes
formed with radiolabeled pre-mRNA are separated by electro-
phoresis. Complexes bound by antibody are identified by their
absence from the native gel. In the immunodepletion experi-
ment of Fig. 6, we included 2 mM EDTA in the splicing reaction.
This results in inhibition of the formation of complexes beyond
the A1 complex and leads to a build up of the A1 complex as
well as prior intermediates (16) Lane 1 shows complexes
formed in an EDTA reaction not treated with antibodies or
beads. The B complex (pre-spliceosome), A2-1, and A1 com-
plexes are seen. As expected in the reaction treated with Prp21
antibody beads, there is quantitative removal of the B complex
(lane 2). In addition, a portion of the A1 complex is removed. In
reactions treated with beads only or buffer only all complexes
remain in the supernatant (lanes 3 and 4). The finding that
only part of the A1 complex was removed suggested that the A1
complex described on these native gels may be composed of two
different species, migrating at or very close to the same posi-
tion. To further characterize the precipitated complex, we re-
peated the immunodepletion experiment in heat-inactivated
extracts from a prp2-1 temperature-sensitive strain. We chose
this mutant extract because the Prp2 protein has been shown
FIG. 5. Immunoprecipitation of U6 snRNA by Prp11 and Prp21
antibodies. Wild type yeast extracts were treated with either the
SRU2 oligo (U2 knock-out, lanes 1, 2, 4, 5, 7, 8, 10, 11) or the d1 oligo
(U6 knock-out, lanes 3, 6, 9, 12). In vitro synthesized, 32P-labeled U2,
U2D107, or U6 snRNA was added as indicated above each lane. H2O
(lanes 1–3, 7–9) or unlabeled actin pre-mRNA substrate (lanes 4–6,
10–12) was then added, and the reactions were incubated for 15 min at
room temperature. Reactions were then added to PAS beads bound with
antibodies to either Prp21 (lanes 1–6) or Prp11 (lanes 7–12) for 30 min
on ice. RNA was recovered, processed, and analyzed as described under
“Materials and Methods.” In most reactions $80,000 cpm of snRNA was
added to the reaction with recovery amounts of no more than 5000 cpm.
FIG. 6. Identification of specific spliceosomal complexes con-
taining Prp21. A standard splicing reaction in a master mix consisting
of yeast extract, splicing buffer, and 32P-actin pre-mRNA was incubated
for 20 min at room temperature to allow formation of spliceosomes. 15
ml of the reaction was then placed on ice after addition of heparin (12
mg/ml final concentration) and Prp21 antibody PAS beads (5 ml of beads
1 5 ml of buffer) and incubated for 30 min. Beads were then pelleted and
a portion of the supernatant was loaded on a 3% native gel. An auto-
radiogram of the gel is shown. Lanes 1–4 show reactions with wild type
yeast extracts performed in the presence of 2 mM EDTA. Lanes 5–8
show reactions with a heat-inactivated prp2-1 mutant extract. Lanes 1
and 5 are control loads of the reaction not treated with PAS. Lanes 2
and 6 are reactions with Prp21 antibody PAS beads; lanes 3 and 6 are
reactions with PAS beads only, and lanes 4 and 8 are reactions to which
buffer only was added. The position of the pre-spliceosome and the two
spliceosomal complexes are indicated by B, A2-1, and A1, respectively.
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to act on the A1 complex.2 Lane 5 shows complexes formed in a
heat-inactivated prp2-1 extract. A small amount of B complex
is formed as well as a complex migrating similar to the A1
complex in EDTA-treated wild type extracts. Visualization of
the A2-1 complex in addition to the B and “A1” complex in
inactivated prp2-1 extracts requires inclusion of EDTA in the
reaction (data not shown). When the prp2-1 extract is treated
with Prp21 antibody beads, virtually all the B and A1 complex
is removed (lane 6). No complexes are removed when the reac-
tion is treated with beads only or buffer only (lane 7 and 8).
Taken together the quantitative binding of Prp21 antibodies to
the A1 migrating complex formed in the prp2-1 mutant extract
and the binding to a portion of the A1 complex in the EDTA-
treated wild type reaction suggest that the A1 complex in the
wild type extract is composed of two different complexes. The
upper complex with reduced mobility is dependent on the ac-
tion of the Prp2 protein and is not immunodepleted by antibod-
ies to Prp21. Thus Prp21 is a component of an A1 complex.
Because Prp11 antibodies also immunoprecipitated a U6-
containing complex, we attempted to perform the spliceosome
complex immunodepletion experiments with the Prp11 anti-
bodies described in Fig. 5. We were unable to see immunodeple-
tion of even the pre-spliceosome complex. This inability to
immunodeplete with Prp11 antibodies may be due to differ-
ences in reaction conditions for the immunodepletion of com-
plexes and the immunoprecipitations described above (i.e. the
presence or absence of heparin in the reactions). However,
based on the immunoprecipitation of U6, Prp11 is very likely
also a component of the A1 and/or another spliceosomal
complex.
DISCUSSION
There are several lines of evidence to suggest that Prp9,
Prp11, and Prp21 interact with each other to form a protein
complex. First, SF3A, the mammalian splicing factor consisting
of the Prp9, Prp11, and Prp21 homologs (SAP61, SAP62, and
SAP114, respectively) (28–31), behaves as a tight protein com-
plex in vitro when subjected to extensive column chromatogra-
phy (32). In addition, far Western type experiments testing
SAP61 and SAP62 with SAP114 showed a direct interaction
between these components of SF3A (28, 33). Second, genetic
analysis of yeast strains carrying any two of the temperature-
sensitive mutations of the prp9-1, prp11-1, or prp21-1 alleles
exhibited a synthetic lethal phenotype, suggesting a tightly
coupled role for these proteins (16, 17). Finally, two-hybrid
experiments performed with the coding regions of Prp9, Prp11,
and Prp21 revealed that these proteins interact in vivo in a
manner consistent with the formation of a Prp9zPrp11zPrp21
complex (22, 23).
Although these lines of evidence are compelling, there had
been no biochemical investigation of the yeast Prp9zPrp11z
Prp21 complex. We have presented here direct physical evi-
dence for the yeast Prp9zPrp11zPrp21 complex and have begun
to characterize the biochemistry of this complex in vitro. First,
we demonstrated a direct interaction between Prp11 and Prp9
and Prp21 by demonstrating that the entire complex is inacti-
vated by heat in prp11-1 or prp21-1 extracts. All three proteins
must be added to regain activity. The formation of a
Prp9zPrp11zPrp21 complex in the absence of any other yeast
proteins was studied by analyzing proteins made in a rabbit
reticulocyte in vitro translation system. Prp9zPrp11zPrp21
formed in vitro is highly stable even at salt concentrations
greater than 0.5 M NaCl. Interestingly, Legrain and colleagues
(23) demonstrated formation of a Prp9 homodimer using the
yeast two-hybrid assay system. We were unable to detect ho-
modimers of either Prp9, Prp11, or Prp21 in our in vitro exper-
imental system. It is possible that observation of homodimer
formation by Prp9 requires an additional factor(s) not present
in our in vitro system.
Previous genetic experiments also demonstrated synthetic
lethal interactions of prp9-1, prp11-1, and prp21-1 with prp5-1
mutants (16, 17). We were unable to detect a direct interaction
between Prp9zPrp11zPrp21 and Prp5, so we investigated the
possibility that the observed genetic interaction between these
proteins was mediated through a functional interaction. In the
accompanying paper (18), we demonstrated that Prp5 medi-
ated an ATP-dependent structural change in the U2 snRNP,
leading to exposure of its branch point region. We hypothesized
that this exposure of the branch point region facilitated inter-
action of the U2 snRNP with the complementary region of the
pre-mRNA. In this paper, we demonstrated that Prp9zPrp11z
Prp21 is necessary for stabilization of a U2 structure that Prp5
can utilize as a substrate.
Based on differences in RNaseH sensitivity of U2 RNA in
mutant extracts, we propose a model in Fig. 7 for changes in U2
snRNP conformation in the activation of the U2 snRNP during
spliceosome assembly. This model describes two “open”
(RNaseH-accessible) states. These two states are differentiated
by whether or not they require ATP to form and by their ability
to assemble into a pre-spliceosome. In the absence of ATP,
there are two (or more) conformational states that are in dy-
namic equilibrium. The open form of the equilibrium is inactive
in pre-spliceosome assembly. In the absence of Prp9, Prp11,
and Prp21 (e.g. in a heat-treated prp9-1 extract), this equilib-
rium favors the inactive, open state. Addition of
Prp9zPrp11zPrp21 in the absence of ATP favors a shift to the
closed state. In the presence of ATP and PRP5 this closed
complex is transformed to an active open state poised for in-
teraction with the branch point sequence of the pre-mRNA.
Ares and colleagues (9, 10) have shown that in the U2 cold-
sensitive mutants G53A and C62U, the U2 snRNA favors an
altered secondary structure or misfolded form that is in equi-
librium with competent snRNP (9, 10). These mutants are
synthetically lethal with prp5-1, prp9-1, prp11-1, and prp21-1
(16, 17). Our investigation of the U2 snRNP in these mutant
extracts indicated that virtually all of the snRNP was in an2 R.-J. Lin, personal communication.
FIG. 7.U2 snRNP activation and spliceosome assembly. A, sche-
matic diagram of the proposed model for Prp5-, Prp9-, Prp11-, and
Prp21-dependent structural changes in the U2 snRNP. B, diagram of
the spliceosomal assembly pathway.
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open conformation even in the absence of ATP. Thus the syn-
thetic lethality could be explained by the lack of a significant
population of Prp9zPrp11zPrp21-associated U2 snRNP for Prp5
to activate. The G53A and C62U mutations affect the equilib-
rium between different forms of the stem II structure of U2
RNA. It is not clear how different forms of this structure could
affect the accessibility of the branch point interaction sequence;
however, recent work by Yan and Ares (34) has identified U2
mutants very close to the branch point pairing sequence that
interact synergistically with mutants in PRP5, PRP9, PRP11,
and PRP21. The mutants are changes in U40, C41, U45, C46,
and U47 just downstream from the branch point interaction
sequence between residues 34 and 39. How changes in the
40–47 region affect U2 function is not clear, but one possibility
is that the mutants enhance pairing with a sequence in U2
between 25 and 30. Such a helical interaction might prevent
the pairing between U2 and the intron. It will be very inter-
esting to find out how mutants in the 40–47 region score in the
RNase H assay.
Other members of the DEAD family of RNA helicases show
characteristic low binding affinities for their RNA substrates
(35, 36). Although the detailed mechanism for specific RNA-de-
pendent ATP hydrolysis and RNA unwinding by these proteins
is not well understood, a possible mechanism could be the use
of auxiliary proteins to facilitate activity and/or specificity. In
the case of eIF-4A, eIF-4B is necessary to stimulate helicase
activity (37). eIF-4B contains an RNP motif suggestive of an
RNA binding function (38). Thus, a possible role for eIF-4Bmay
be to stabilize or enhance RNA structures suitable for use as
substrate by eIF-4A. Analogously, it has been shown that
Prp9zPrp11zPrp21 binds to the U2 snRNP (27) and stabilizes
the RNaseH inaccessible (“closed”) form of the U2 snRNP that
is a substrate for Prp5 (this work). The availability of purified
Prp9zPrp11zPrp21 protein complex should greatly facilitate in-
vestigation of potential Prp5 RNA helicase activity in vitro.
A Role for Prp9zPrp11zPrp21 after Pre-spliceosome Assem-
bly—We have described convincing evidence that
Prp9zPrp11zPrp21 associates with U2 and ultimately with the
pre-spliceosome. Identifying possible roles of these proteins
later in the spliceosome assembly pathway has been more
difficult. Using a highly sensitive snRNA immunoprecipitation
protocol based on the U6 knock out/reconstitution system (19),
we have detected the presence of Prp9zPrp11zPrp21 in U6
snRNA containing spliceosomal complexes. Although we only
directly detected co-immunoprecipitation of U6 with antibodies
to Prp11 and Prp21, we favor the hypothesis that interactions
detected with any one of the components of Prp9zPrp11zPrp21
represent the presence of the complex. This is because
Prp9zPrp11zPrp21 is a highly stable complex under the in vitro
conditions of the splicing assay. However, we cannot rule out
the possibility that the complex is disrupted during spliceo-
some assembly. A diagram of the spliceosome assembly path-
way is shown in Fig. 7B. We found that Prp21 could be identi-
fied as an integral component of an A1 complex. In earlier
experiments (18) we did not detect a decrease in the U6-con-
taining complexes in a Prp21 immune depletion experiment.
This was probably because only part of complex A1 is depleted
in these experiments, and the fraction that is in that form may
depend on the experimental conditions. We were unable to
detect Prp9zPrp11zPrp21 in the other U6-containing complexes,
A2-1 and A2-2. It seems unlikely that Prp9zPrp11zPrp21 leaves
the complex and returns at the later A1 stage, so we attribute
the failure to deplete to conformational differences in these
complexes leading to destabilization of Prp9zPrp11zPrp21 or to
conformational differences that lead to inaccessibility of the
epitope for immunoprecipitation.
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